The selected lead antibodies were selected by Aboundbio from a massive antibody library for ultra-specificity for SARS-CoV-2, as indicated by the absence of binding to over 5,300 proteins in the human cell surface proteome. Preclinical cell culture models did not induce antibody-dependent enhancement of infection and were effective at low doses in mouse and hamster models of SARS-CoV-2 infection.

Under the agreement, antibody production and clinical development for regulatory approval and commercialization will proceed in the Middle East and North Africa (MENA) and the Association of Southeast Asian Nations (ASEAN) regions by SaudiVax. This biotechnology company based in Saudi Arabia is a joint venture between UYC of Saudi Arabia and PnuVax of the U.S.

Regeneron begins COVID-19 antibody treatment phase III trial
Regeneron Pharmaceuticals has begun adaptive late-stage phase III clinical trials evaluating its antibody cocktail, REGN-COV2, for the treatment and prevention...

Affinity finds potent SARS-CoV-2 antibodies
Australian cancer therapeutics company Affinity Biosciences has discovered potent SARS-CoV-2 antibodies with potential therapeutic applications against...

ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further...

Integral Molecular aids with safety testing of COVID-19 antibodies
Integral Molecular is applying its membrane proteome array technology for antibody specificity profiling to accelerate development of SARS-CoV-2 therapeutic...

Oblique Therapeutics identifies epitope for SARS-CoV-2 antibodies
Oblique Therapeutics has used its Abiprot antibody discovery platform to identify an epitope in SARS-CoV-2 that may facilitate the generation of new neutralizing...